Form 4: Cero Therapeutics CFO Acquires 500,000 Stock Options
SEC Form 4 Filing
Andrew Kucharckuk, CFO of Cero Therapeutics Holdings, Inc., reports the acquisition of 500,000 stock options.
Summary
- Andrew Kucharchuk, the Chief Financial Officer of Cero Therapeutics Holdings, Inc. acquired 500,000 stock options on October 1, 2024.
- The options have an exercise price of $0.10.
- The options vest in twelve monthly installments following the grant date, contingent upon continued service.
- The expiration date for these options is September 30, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which doesn't inherently indicate positive or negative sentiment.
Positives
- The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies.
Stakeholder Impact
- The granting of stock options aligns the CFO's interests with those of the shareholders, potentially incentivizing him to improve company performance.
Key Dates
| Date | Description |
|---|---|
| 10/01/2024 | Date of stock option acquisition |
| 10/02/2024 | Date of Form 4 filing |
| 09/30/2034 | Expiration date of the stock options |
Keywords
stock options, CFO, Cero Therapeutics, Form 4, beneficial ownership, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.